Author: workdigital2701@gmail.com

As of Friday evening, 234 Covid active cases have been reported in Karnataka.

In view of the Covid-19 situation in the state and the reopening of schools, Karnataka government, in a circular, has asked parents not to send their children to school, if they have fever, cough, cold and other symptoms.

The Commissioner, Health and Family Welfare has issued the circular late for precautions to be taken in government and private schools, as instructed during the Covid-19 situation review meeting chaired by Chief Minister Siddaramaiah held on May 26.

“If fever, cough, cold and other symptoms are found in school children, do not send the children to school and follow appropriate treatment and care measures as per doctor’s advice,” the circular, issued late on Friday, said.

It instructs for sending children to school only after complete cure.

If children come to school with fever, cough, cold and other symptoms, inform their parents and send them back to home, the Health Department further said that if these symptoms are found among the school teachers and non-teaching staff, they should be advised to follow appropriate precautionary measures.

It also calls for ensuring adherence to precautionary measures like hand hygiene, cough etiquette and other Covid 19 Appropriate Behavior (CAB).

Overall, strict adherence to Covid-19 precautionary measures has been instructed in the interest of the health of school children,” it added.

As of Friday evening, 234 Covid active cases have been reported in the state. Three patients with the infection, who had other comorbidities, have died since January 1.

Symptoms of NB.1.8.1 are generally mild to moderate. However, elderly and immune-compromised people remain at higher risk for severe disease.

India has reported a total of 3,961 active Covid-19 cases so far. According to the Ministry of Health and Family Welfare data, 203 fresh infections were recorded in the last 24 hours. Kerala has reported the most cases, with 1,435, followed by Maharashtra with 506 and Delhi with 483 cases. Four people have succumbed to the virus during the ongoing resurgence of Covid-19.

The new highly transmissible variant NB.1.8.1, descendants of the JN.1 variant has contributed to a surge in Covid-19 cases. The JN.1 variant and its related descendants belong to the Omicron family. Along with NB.1.8.1, the LF.7 strain is also circulating rapidly.

Symptoms of NB.1.8.1

According to the Centers for Disease Control and Prevention (CDC), the NB.1.8.1 strain has triggered a sharp rise in hospitalisations across China and has also been detected in the United States.

Symptoms are generally mild to moderate. However, elderly and immune-compromised people remain at higher risk for severe disease. NB.1.8.1 may not cause severe illness, however, it spreads faster than other variants.

Do you need a covid test?

Covid cases are rising and so are flu cases, the need for covid testing has become more important than ever. Do you really need a covid test? Here are the health ministry guidelines you should follow.

“All individuals need not be tested, because disease is primarily reported in individuals with travel history to the affected countries or close contacts of positive cases,” mentions the health ministry.

According to the health ministry, all symptomatic people need a covid test if:

• You have a history of international travel in the last 14 days
• You came in contact with confirmed cases
• You are a healthcare provider
• You are hospitalized patients with Severe Acute Respiratory Illness (SARI) influenza-like illness (ILI) or severe pneumonia.

“Asymptomatic direct and high-risk contacts of confirmed cases should be tested once between day 5 and day 14 of coming in his/her contact,” the health ministry mentions.

Direct and high-risk contact includes those living in the same household with a confirmed case and healthcare workers who examined a confirmed case without adequate protection as per WHO recommendations.

the number of total active Covid-19 patients reached 311, with 87 persons testing positive for the infection in the last 24 hours, the Health and Family Welfare department said on Monday.

Karnataka’s Health and Family Welfare Department has said in an official statement that the number of active Covid-19 cases crossed the 300-mark in the state.

As the most of the schools reopened on Monday after summer vacations, the authorities are on high alert.

The number of total active Covid-19 patients reached 311, with 87 persons testing positive for the infection in the last 24 hours, the Health and Family Welfare department said on Monday.

As many as 504 persons were tested across the state.

A total of 29 persons were discharged during the same period.

The Covid-positivity rate stood at 17.2 per cent and case fatality rate is zero per cent.

Among the total 311 patients, 297 are kept in home quarantine and 14 admitted to hospitals, three are in Intensive Care Units of the government and private hospitals.

Amid the fear of Covid-19, the authorities are worried over the increasing number of the Severe Acute Respiratory Infection (SARI) and influenza cases.

According to sources in the Health department, the total number of SARI and influenza cases have increased to 4,536 cases in the state since January this year.

In the last week, 154 SARI cases have been reported in the state.

The officials said that they are seeing a trend of steep rise in number of such cases.

The government is arranging for Covid-19 tests for the patients affected with SARI and influenza.

The doctors have warned people not to neglect the symptoms of fever, cough, fatigue, nose blockage, running nose, headache, breathing issues, and throat pain.

The capital Bengaluru continues to be hotspot for Covid-19 as most active cases are reported from here.

Meanwhile, State Health Minister Dinesh Gundu Rao said that the Gruha Arogya Yojana (Home Health Scheme) is being expanded across the state, with 14 non-communicable diseases included for screening under the programme.

The Minister added that non-communicable diseases pose a significant threat to people’s lives.

While the private healthcare sector prioritises treatment, it is crucial to prevent non-communicable diseases proactively.

He emphasised that the government should undertake this task, as others may not show interest.

As a responsible government, the State Health Department is expanding the Gruha Arogya Yojana statewide to prevent non-communicable diseases, the Minister said.

Minister Rao also added that the programme will screen individuals aged above 30 years in every household and ensure that appropriate medicines reach them.

The project was implemented in Kolar district initially.

There are 4,026 active cases in India and five fresh deaths have been reported in the last 24 hours.

India’s active COVID-19 cases have crossed the 4,000 mark, with Kerala remaining the most affected state followed by Maharashtra, Gujarat, and Delhi, according to the Union Health Ministry data released on Tuesday.

There are 4,026 active cases in India and five fresh deaths have been reported in the last 24 hours.

Since January this year, 37 deaths have been reported in the country.

There were 257 active patients in the country on May 22. The figure rose to 3,395 by May 31 and subsequently to 4,026 cases.

Presently, Kerala has 1,446 active cases, the highest in the country followed by Maharashtra with 494, Gujarat with 397 and Delhi with 393 cases.

Five deaths —one each in Kerala, Tamil Nadu and West Bengal and two deaths in Maharashtra — have been reported in the last 24 hours, according to the data.

Official sources on May 31 stated that the COVID-19 situation in India is being closely monitored while stressing that the severity of infections is low, with most of the patients being under home care and that there was no cause for worry.

Director General of Indian Council of Medical Research (ICMR) Dr Rajiv Behl on Monday stated that genome sequencing of samples in West and South have shown that the variants leading to the current rise in cases are not severe and are sub variants of Omicron only.

The four variants that we have found are subvariants of Omicron — LF.7, XFG, JN.1 and NB. 1.8.1. The first three have been found in more number of cases, he said.

“We have been closely monitoring the situation. At this moment overall, we should monitor, be vigilant but there is no cause to worry,” Dr Behl had said.

A team of US researchers has developed a new type of mRNA vaccine that is more scalable and adaptable to tackle continuously evolving viruses such as SARS-CoV-2 and H5N1.

Amid fresh surge in Covid-19 cases, a team of US researchers has developed a new type of mRNA vaccine that is more scalable and adaptable to tackle continuously evolving viruses such as SARS-CoV-2 and H5N1.

While the currently available mRNA vaccines are highly effective at inducing an immune response against Covid, they present challenges like the high amount of mRNA needed to produce them and the constantly evolving nature of the pathogen.

“The virus changes, moving the goal post, and updating the vaccine takes some time,” said senior author Suresh Kuchipudi, chair of Infectious Diseases and Microbiology at the University of Pittsburgh School of Public Health.

To address these challenges, the researchers created a proof-of-concept Covid vaccine using what’s known as a “trans-amplifying” mRNA platform.

In this approach, the mRNA is separated into two fragments — the antigen sequence and the replicase sequence — the latter of which can be produced in advance, saving crucial time in the event a new vaccine must be developed urgently and produced at scale.

In addition, the researchers analysed the spike-protein sequences of all known variants of the SARS-CoV-2 for commonalities, rendering what’s known as a “consensus spike protein” as the basis for the vaccine’s antigen.

In mice, the vaccine induced a robust immune response against many strains of SARS-CoV-2.

“This has the potential for more lasting immunity that would not require updating, because the vaccine has the potential to provide broad protection,” said Kuchipudi.

“Additionally, this format requires an mRNA dose 40 times less than conventional vaccines, so this new approach significantly reduces the overall cost of the vaccine.”

The study, published in the journal npj Vaccines could inform more efficient vaccine development for other constantly evolving RNA viruses with pandemic potential, Kuchipudi said.

“We hope to apply the principles of this lower-cost, broad-protection antigen design to pressing challenges like bird flu.”

Welcome to WordPress. This is your first post. Edit or delete it, then start writing!